What Transformation Has the Non-Therapeutic Biomolecules Market Undergone?
The non-therapeutic biomolecules market has seen considerable growth due to a variety of factors.
• Over the recent years, the market size of non-therapeutic biomolecules has shown accelerated growth. The market that valued at $30.76 billion in 2024 is projected to expand to $34.23 billion in 2025, following a compound annual growth rate (CAGR) of 11.3%. This notable growth during the historic period is a result of amplified investments in research and development (R&D), an expansion in their applications in research and diagnostics, increased awareness and adoption, strategic collaborations and partnerships, and regulatory support.
What Are The Predictions for The Non-Therapeutic Biomolecules Market Size?
The Non-Therapeutic Biomolecules market is expected to maintain its strong growth trajectory in upcoming years.
• The market for non-therapeutic biomolecules is projected to experience significant expansion in the coming years, with an estimated worth of $52.15 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 11.1%.
This projected growth over the forecast period can be traced back to factors such as burgeoning market opportunities, the advancement in data analytics and integration, an increasing focus on precision medicine, heightened investment in personal healthcare, and widening application areas. The prediction period is marked by numerous trends like technological innovation, strategic partnerships, burgeoning applications in farming, an enhanced role in industrial operations, alongside customization and personalization.
Which Drivers Are Accelerating Growth In The Non Therapeutic Biomolecules Market?
The surge in research activities and lab testing is projected to stimulate the non-therapeutic biomolecules market's expansion. Laboratory testing is a medical process that requires testing bodily fluids like blood or urine to diagnose and monitor disease and formulate a treatment strategy, while research implies the creation of new knowledge or innovative application of existing awareness to develop new concepts, theories, and insights. Non-therapeutic biomolecules are used in lab testing to ascertain the existence or concentration of a biomarker molecule indicative of a disease, improving the test's sensitivity and accurateness. For example, the National Health Service (NHS), a hospital and healthcare provider based in the UK, reported in July 2024 that diagnostic activity in May 2024 had surpassed pre-pandemic levels in 2023, reflecting a 21% uptick in tests administered compared to the prior year. Consequently, the escalating number of research and lab tests is fuelling the growth of the non-therapeutic biomolecules market.
What Are The Core Segments Of The Global Non Therapeutic Biomolecules Market?
The non-therapeutic biomolecules market covered in this report is segmented –
1) By Trad Pharma: Enzymes, Recombinant Proteins, Plasmids, Peptides, Oligonucleotides, Monoclonal Antibodies
2) By End User: Research, Pharma, In Vitro Diagnostics(IVD)
Subsegments:
1) By Enzymes: Industrial Enzymes, Diagnostic Enzymes
2) By Recombinant Proteins: Antigens, Cytokines, Growth Factors
3) By Plasmids: Research Plasmids, Expression Plasmids
4) By Peptides: Antimicrobial Peptides, Signaling Peptides
5) By Oligonucleotides: Antisense Oligonucleotides, RNAi Oligonucleotides
6) By Monoclonal Antibodies: Research Antibodies, Diagnostic Antibodies
Pre-Book The Non Therapeutic Biomolecules Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Emerging Trends Are Reshaping The Non Therapeutic Biomolecules Market Size?
The trending emphasis on product innovations within the non-therapeutic biomolecules market is a notable development. The key players in this sphere are increasingly investing in R&D for innovative products in order to maintain their market standing. A case in point is BASF SE, an established multinational chemical firm from Germany, which initiated a collaboration with Caregen, a South Korean entity specializing in biomimetic peptide research and development. In January 2022, this partnership gave birth to the Peptovitae series, developed via liposome-encapsulation technology, thus enriching their dermo-cosmetic product lines. This liposomal encapsulation approach involves employing fats to transport vital vitamins or medications to specific areas in the body using microscopic bubbles, without any impact on other parts. Thus, the Peptovitae series offers a more comprehensive approach to addressing skin issues than what is conventionally associated with peptide use, tackling concerns like signs of aging, brightening the skin's appearance, alleviating dryness and itchiness, and providing skin hydration.
Who Are the Key Players In The Non Therapeutic Biomolecules Market?
Major companies operating in the non-therapeutic biomolecules market include:
• Amgen Inc.
• Genentech Inc.
• Merck KGaA
• Lonza Group AG
• Bio-Rad Laboratories Inc.
• Thermo Fisher Scientific Inc.
• Agilent Technologies Inc.
• Charles River Laboratories International Inc.
• GE Healthcare Life Sciences
• Fujifilm Diosynth Biotechnologies
• Evonik Industries AG
• Seikagaku Corporation
• Takeda Pharmaceutical Company Limited
• MilliporeSigma
• Covance Inc.
• Sartorius AG
• Sanofi S.A.
• CordenPharma International
• Bayer AG
• WuXi AppTec
• Ginkgo Bioworks
• Synlogic Inc.
• 3M Company
• Eppendorf AG
• Medtronic Plc
• Bio-Techne Corporation
• Iovance Biotherapeutics Inc.
• Vectalys
• Avid Bioservices Inc.
• Sientra Inc.
What Are The Regional Insights Into The Non Therapeutic Biomolecules Market?
Asia-Pacific was the largest region in the non-therapeutic biomolecules market share in 2024. The regions covered in the non-therapeutic biomolecules market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
